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This thesis investigates the functions and prospective of
Pramlintide, a drug used in combination with insulin for
diabetes type 1 patient. This drug has been approved by
FDA in late 2005 and it's being commercialized nowadays
only in USA.The aim of this thesis is to develop a mathe-
matical model which allows the quantitation of the eect
of Pramlintide and to incorporate it into the meal sim-
ulation model of the glucose-insulin system. So starting
with the introduction of what this new medicinal is, I go
through a description of its dynamics, than I go through
the model description and its inclusion in a Glucose-Insulin
simulation model. These latest in silico experiments should
nally prove the benets of Pramlintide action vs a usual
insulin treatment.
Due the fact that all therapy are focused on insulin thera-
pies, the addiction of Pramlintide makes the blood glucose
control problem less \insulincentric" giving the opportu-
nity to achieve a better results in either diabetes mellitus
type 1 and 2.Sommario
Questa Tesi e' proposta in inglese poiche' sviluppata negli
Stati Uniti d'America presso il centro di tecnologie per il
diabete dell'University of Virginia nel 2012. In questa tesi
ci si propone di investigare le possibilita' di un farmaco che
si chiama Pramlintide, in commercio solo negli USA, che
e' usato per la cura del diabete mellito sia di tipo 1 che 2.
Partendo da cosa sia e quali sono i suoi eetti siologici, si
passa ad una descrizione modellistica della sua dinamica.
Una volta identicato l'opportuno modello di azione, sia
nel caso di soggetto medio che individuale, con le relative
ipotesi statistiche, lo inserisco per prove in silico in un
simulatore del sistema Glucosio-Insulina, per dimostrare
cosi', l'eettiva ecacia di questo nuovo medicinale. Quello
che mi aspetto da questo farmaco e' un migliore controllo
della concentrazione del glucosio, specialmente dopo un pasto.
Il trattamento con Pramlintide non sostituisce quello rego-
lare insulinico, ma lo integra.Contents
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2Chapter 1
Introduction
1.1 Diabetes
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting
from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of
diabetes is associated with long-term damage, dysfunction, and failure of various organs,
especially the eyes, kidneys, nerves, heart, and blood vessels[1].
1.1.1 Diabetes mellitus type 1
Diabetes mellitus type 1 (Type 1 diabetes, T1DM, IDDM, or, formerly, juvenile diabetes)
is a form of diabetes mellitus that results from autoimmune destruction of beta-cells of
the pancreas. The subsequent lack of insulin leads to increased blood and urine glucose.
The classical symptoms are polyuria (frequent urination), polydipsia (increased thirst),
polyphagia (increased hunger), and weight loss. All these causes are due to the fact that
the type 1 body is not able to use glucose as energetic source but uses other nutrients like
fats. Type 1 is induced by genetically factors and usually appears in young age. It requires
external insulin to make the subject live. Less than 10% of diabetes suers of type1.
1.1.2 Diabetes mellitus type 2
Diabetes mellitus type 2 (formerly non-insulin-dependent diabetes mellitus (NIDDM) or
adult-onset diabetes) is a metabolic disorder that is characterized by hyperglycemia in the
context of insulin resistance and relative insulin deciency. The development of type 2
diabetes is caused by a combination of lifestyle and genetic factors. While some are under
3personal control such as diet and obesity others such as increasing age, female gender, and
genetics are not. It presents the same symptoms of type 1 and more compliances.The 90%
of diabetes suer of type 21 .
This paper regards mostly the case of diabetes type 1 and some references to the type 2. The
other sort of non-mellitus diabetes, e.g. diabetes insipidus2, is not topic of interest.
1.1.3 Epidemiology
Figure 1.1: European Estimation Risk by
IDF, 2007.
Standing to United Nations publications
the diabetes population is 6% of world pop-
ulation, it's about 240 millions of people.
Time ago diabetes was mostly in the in-
dustrialized countries where the life style
helped the disease. Nowadays diabetes
is growing in the developing country, e.g.
Central America and Arabia (Fig. 1.1, 1.2
and 1.3) due the new junk food available
to low-class people. Diabetes hits both
men and women in a range between 20 and
79 years old (unfortunately its growing in
younger generation). WHO (World Health
Organization) denes diabetes as epidemic,
in fact the statistic says that diabetes has
an exponential increase and in the 2025 the
diabetics will be 380 millions, in which 80%
from medium/low income country. WHO projects that diabetes deaths double from 2005
to 2030. This important disease is also expensive to cure. Its estimated that USA and
Europe use 15/20% of health resources for diabetes, of which the 38% are used for the
terrible diabetes compliances like ischemia, heart diseases, renal insuciency and so on.
For example the disease was estimated to cause $10.5 billion in annual medical costs ($875
per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month
per diabetic)[2].
1In the 10% of not type 2 there aren't only the type 1, also the gestational diabetes ( 2% of diabetes
population): this type of diabetes occurs in women who never had diabetes before but in pregnancy they
present high glucose level.
2A rare disease due vasopressin dysfunction caused by a brain damage.
4Figure 1.2: See how the middle income countries (e.g. Mexico, Brazil or Saudi Arabia) are
in an alarming condition about their diabetes prevision.
.
5Figure 1.3: American Map: alarming data are estimated from US population (by US Health
Center). Nowadays one third is overweight and another one third is obese, all conditions,
especially the second one, which helps diabetes developing.
61.2 Physiology of Glucose and Insulin System
Insulin, a catabolic protein hormone, is secreted by beta-cells of pancreas. Its main func-
tion is to lower glycemia, i.e. the blood sugar (glucose) concentration when its high. Its
antagonist is the glucagon, which is released by alpha-cells of pancreas with the function
of raising the BG (blood glucose) whenever this is too low. This synergetic action is well
regulated in healthy subjects. In fact when the glycemia raises, e.g after a meal, the glucose
sensors, placed in many bodys parts, stimulate the release of insulin. This hormone gets
the membrane of specic tissues more permeable: these tissues are called insulin dependent
tissues. At this classes of tissues belong all tissues that need insulin for better using the
glucose energy and store the glucose under glycogen, the human glucose reserve, lowering
the BG (striated muscle, the heart, the lipid tissue and also could be the liver). It also,
inhibits the gluconeogenesis in the liver and promotes the stocking of triglycerides as fat
tissue (lip genesis). As the antagonist, glucagon stimulates the breaking of glycogen (glycol-
ysis) and promotes the gluconeogenesis in the liver increasing the glucose 
uxes on blood.
Figure 1.4: Glucose-Insulin regulation.
Moreover there are tissue
that are strictly depen-
dent on glucose and in-
dependent on insulin ac-
tion. The glucose de-
pendent tissues (or in-
sulin independent tis-
sues) need glucose for
survive and consume it
almost-constantly during
the day: they're the
brain, the kidney and
erythrocyte. Its impor-
tant to remind that a
meal is not usually only
the ideal glucose dose but
a mixed meal, in fact in-
sulin rises in blood con-
centration with all sort
of meal like proteins and
fats not only with sugars[3].
1.2.1 Hypoglycemia vs. Hyperglycemia
7Figure 1.5: Glucose (red Line) and Insulin (blue line) patterns
during a normal day in healthy subject.
Hypoglycemia is a con-
dition that occurs when
the BG is too low.
Throughout a 24-hour
period blood plasma glu-
cose levels are generally
maintained between 4-
8 mmol/L (72 and 144
mg/dL)
3 .
Although 3.3 or 3.9 mmol/L
(60 or 70 mg/dL) is
commonly cited as the
lower limit of normal glu-
cose, symptoms of hypo-
glycemia usually do not
occur until 2.8 to 3.0
mmol/L (50 to 54 mg/dL). The precise level of glucose considered low enough to dene
hypoglycemia is dependent on: the measurement method, the age of the person, presence
or absence of eects, and the purpose of the denition. While there is no disagreement as
to the normal range of blood sugar, debate continues as to what degree of hypoglycemia
warrants medical evaluation or treatment, or can cause harm. Hypoglycemic symptoms
and manifestations can be divided into those produced by the counter-regulatory hormones
(epinephrine/adrenaline and glucagon) triggered by the falling glucose, and the neurogly-
copenic4 eects produced by the reduced brain sugar. Hyperglycemia or high blood sugar
is a condition in which an excessive amount of glucose circulates in the blood plasma.
This is generally a glucose level higher than (200 mg/dl). Reference test range for blood
tests are 11.1 mmol/l, but symptoms may not start to become noticeable until even higher
values such as 250-300 mg/dl or 15-20 mmol/l. A subject with a consistent range above
126 mg/dl or 7 mmol/l is generally held to have hyperglycemia. Chronic levels exceeding
7 mmol/l (125 mg/dl) can produce organ damages. The damage of this ones are basically
associated to a chronic status like diabetes mellitus. Fast BGs peaks are considerate not
danger, but recent studies show how these isolates hyperglycemia episodes but frequently
during a day or a week (in a short time generally and in p.p. period) comport microvascu-
3Glucose concentrations are expressed as milligrams per deciliter (mg/dL or mg/100 mL) in the United
States, Japan, Spain, France, Belgium, Egypt, Saudi Arabia and Colombia, while millimoles per liter
(mmol/L or mM) are the units used in most of the rest of the world. Glucose concentrations expressed as
mg/dL can be converted to mmol/L by dividing by 18.0 g/dmol (the molar mass of glucose).
4Shortage of glucose in the brain. It aects the neuronal function altering brain functions and behavior.
Recurrent or prolonged it could take the subject to brain damage, coma and then death.
8lar diseases[5]. So its the aim of physicians and engineers maintain the BG in the normal
range (euglycemic) lowering the peaks of glucose (especially after a meal) but absolutely
avoiding the possibility of hypoglycemia. Also it will be good reducing the BG variability
during short time therapy[4].
1.2.2 Gastric Emptying
Despite all glucose 
uxes have been basically attributed to an interaction between insulin
and glucagon, one of them, the rate of appearance of glucose on blood (i.e. how the sugar
passes from the digestive system to blood), has not. Indeed only 50% can be explained
with usual insulin-glucagon system. The other 40/50% can be explained with the gastric
emptying system[7]. The gastric emptying is a complex body's feedback regulation that
permits to control the rate of release of glucose from splanchnic organ to bloodstream (Rate
of appearance, Ra). Indeed when the BG is too high, the Ra is slowed down, otherwise
the Ra is speeded. Gastric emptying is modulated by feedback mechanisms arising from
the interaction of nutrients with the small intestine. Diabetes type1 has a dicult gastric
emptying regulation and the main reason is the lack of a hormone, the amylin[6]. This
Figure 1.6: In the gure we see a quick rate of appearance in diabetes with exogenous
insulin (white dotted) vs. normal subject (black dotted) in postprandial period (p.p., i.e.
is the time, about 2 hours, after a meal. The opposite is preprandial period.) . In diabetes
the fast Ra can produce a quick hyperglycemia which even if is not so dangerous its recently
considered harmful.
entails a dierent Ra than healthy subject (Fig.1.6).
91.2.3 A1C
The American Diabetes Association (ADA) assesses a good diabetes therapy referring to
A1C parameter. A1C or Glycated Hemoglobin or HbA1c is a form of hemoglobin that is
measured primarily to identify the average plasma glucose concentration over prolonged
periods of time. Normal levels of glucose produce a normal amount of glycated hemoglobin.
As the average amount of plasma glucose increases, the fraction of glycated hemoglobin
increases in a predictable way . This serves as a marker for average blood glucose levels over
the previous months prior to the measurement. In the 2010 ADA Standards of Medical
Care in Diabetes added the A1c greater equal to 48 mmol/mol (greater equal to 6.5%
from normal value) as another criterion for the diagnosis of diabetes. In diabetes mellitus,
higher amounts of glycated hemoglobin, indicates poor control of blood glucose levels. But
A1C tests doesn't measure your day-to-day control. You can't adjust your insulin on the
basis of your A1C tests. That's why your blood sugar checks and your lag of results are
so important to staying in eective control. ADA xes the AIC target at <7% for a good
diabetes treatment[1].
1.3 Regular therapies for type 1
Type 1 is treated with insulin replacement therapy (insulin therapy), either via subcu-
taneous injection or insulin pump (or an insulin pump that inject subcutaneously, CSII),
with attention to dietary management, typically including carbohydrate tracking, and care-
ful monitoring of BG levels using glucose meters5. Today, the most common insulin are
biosynthetic products produced using genetic recombination techniques; formerly, cattle or
pig insulin were used, and even sometimes insulin from sh[8]. A more recent trend, from
several suppliers, is insulin analogs, which are slightly modied insulin with dierent onset
or duration of action times (mostly is used in combination: the fast insulin after the meal,
and the slow one for night). As said before untreated type 1 diabetes commonly leads
to coma, often from diabetic ketoacidosis, which is fatal if untreated. Continuous glucose
monitors (CGM) have been developed and marketed. This device can alert patients to the
presence of dangerously high or low blood sugar levels, in fact this technique allows the
almost constant monitoring of BG and a minimum of invasiveness. But technical limita-
tions have slowed the impact of these devices on clinical practice so far. Hypoglycemia is
a very common occurrence in people with diabetes in treatment; usually its the result of
a mismatch in the balance among insulin, food and physical activity, although the non-
physiological method of delivery also plays a role[9]. In more extreme cases, a pancreas
5The most common are the home version (HBGM): a small drop of blood, obtained by pricking the
skin with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood
glucose level (self test). The meter then displays the level in mg/dl or mmol/l.
10transplant can restore proper glucose regulation. However, the surgery and accompanying
immunosuppression required is considered by many physicians to be more dangerous than
continued insulin replacement therapy, so is generally only used with or some time after a
kidney transplant[10]. Experimental replacement of beta cells (by transplant or from stem
cells) is being investigated in several research programs. Islet cell transplantation is less
invasive than a pancreas transplant[11].
1.4 Pramlintide
Pramlintide6 is the synthetic analog of human amylin. Amylin (IAPP) is a human hormone
(protein) co-secreted with insulin by beta-cell islets in pancreas. It is the second beta-cells
hormone[14]. The secretion pattern of both peptides during glucose or glucose plus arginine
stimulation is identical (Fig. 1.8). The molar ratio of amylin amounts to 10% of that of
insulin[15].
Figure 1.7: Amylin vs Pramlintide molecules:
the twos are identical a part an amino acid
substitutions.
The pramlintide is a drug approved by FDA
in 2005, and it's the only second drug ap-
proved for T1 diabetes after insulin that
was approved in early twentieth century .
Amylin has essentially two main functions
(pramlintide either) in human body (Fig.
1.10):
1. MEAL DERIVED FUNCTION: slows
the gastric emptying in response of
meal;
2. LIVER DERIVED FUNCTION: par-
ticipate in glucagon regulation[12].
Secreted in blood stream with a pattern
similar to insulin amylin is absent in type1
patients as well as insulin as shown in Fig.
1.9 where there's a comparison between of daily pattern of insulin vs amylin in dierent
amplitude scale.
In diabetes things change and it is well shown in the graphic (Fig 1.9) below where amylin
concentration in T1 is basically not existent and in T2 is lower than healthy[13].
6Amylin Pharmaceutics Inc., San Diego, CA, USA.
11Figure 1.8: Insulin(empty dots) vs Pramlintide (triangle dots) with three meals.
.
1.5 Therapies with pramlintide in type 1
Many type 1 diabetic patients, if not most, don't achieve and don't sustain, for long
time, the optimal glucose prole just using injected insulin (even with CGM, CSII and
insulin rapid and slow technologies) due to physiological barriers. The barriers are mainly
these:
1. The exogenous insulin (subcutaneous and peripheral) has not the same dynamic
of real one (plasmatic): the interstitial injection instead plasmatic and peripheral
instead portal circulation creates delays and problems in control. For instance the
injection in peripheral part of body gets liver unable to suppress appropriately the
glucagon action (it doesn't have the insulin ready in its area), causing a systematic
high BG. So the external controller injects more insulin increasing the risk of in
hypoglycemia without counting that more insulin it's used more is the risk of weight
gain.7.
7Insulin helps the fat genesis[25]
12Figure 1.9: Amylin pattern in healthy, T2 and T1 subjects.
.
2. In diabetes is well known the high level of glucagon in p.p. period. The cause is not
so certain but this issue takes quickly the system in hyperglycemia in p.p. period
until the external amount of insulin inhibits its production.
3. The less considerate contribution of gastrointestinal tract to glucose regulation: Ra,
in fact, is a determinant factor of p.p. glucose pattern in
uenced by, not only the
amylin, but also by secondary hormones, e.g. CCK, GLP-1 and GIP.
The pramlintide must be injected with regular insulin therapy but in dierent siring. It
cannot be alone as a solo treatment[17]. The rst studies about pramlintides benets in
2003 showed how the injection of pramlintide with either regular or rapid insulin lowers
glucose excursion after a meal8. But their main result was that diabetes must take this drug
during or just before eating to see the best results (full squared and full dotted patterns,
Figure 1.11)
It's noticeable that in insulin lispro (a brand of rapid insulin) the action of the rapid insulin
with all sort of pramlintide injection take the system in hyper BG. This issue is probably
due to the fast insulin, which disappears quickly than regular. Other thing: in pramlintide
therapy it should be used less insulin, about 30% less at each meal, to lower the potential
of weight gain and overall to avoid the hypoglycemic area. Moreover the AUC is reduced
signicantly: this parameter is important for set controller and parameters for diabetes (as
8Standard mixed breakfast at 7.00 am in 5 minutes after a fast night.
13Figure 1.10: Amylin physiological system.
14Figure 1.11: Dierent p.p. periods patterns for a pramlintide treatment. From either A
(regular insulin) and B(rapid insulin) experiments, it's clear that the best pattern results
from the administration of pramlintide at or just before the meal ingestion.
.
15insulin sensitivity). Lowering the pp glucose excursion is the main visible eect of pram-
lintide in diabetes T1.[18] This is physiologically due to the double action (meal derived
and liver derived) of this drug, which simulating the amylin, delays the gastric emptying,
allowing a slower glucose releasing on blood, and suppresses glucagon production, lowering
the glucose production on blood. Experimental investigations in rodents indicate that the
eects of amylin, and by inference pramlintide, on nutrient delivery (gastric emptying) are
mediated via a central pathway that involves the area postrema and visceral eerents of
the vagus nerve[26]. The area postrema in the brainstem contains a high density of amylin
binding sites, and it is exposed to changes in plasma amylin and glucose concentrations
because it does not have a blood-brain barrier[27]. Selective lesioning of the area postrema
and/or bilateral vagotomy abolishes the eect of amylin on gastric emptying, demonstrat-
ing the importance of this central pathway in mediating amylins physiological functions[28],
Fig.1.10. The second function is a very clever regulation; indeed the amylin begins to sup-
press glucagon production after a meal trigger. The suppression continues till the BG is
in euglycemic range but stops when the BG goes in hypoglycemic status[29].
Another interesting nding was that the addition of pramlintide to insulin therapy also
reduced postprandial triglyceride excursions, an eect that might be attributable to pram-
lintide's eect on gastric emptying. By slowing the delivery of all nutrients (carbohydrates,
lipids, and proteins) from the stomach to the small intestine, pramlintide likely tempers
not only the in
ow of glucose into the circulation, but also the in
ow of chylomicrons
and other meal-derived lipoproteins. This may help to better match the patients capacity
for lipoprotein clearance, thereby limiting the postprandial triglyceride excursion. Given
that many patients with diabetes experience postprandial hyper- and dyslipidemia, and
that this abnormality has been implicated as a potential cardiovascular risk factor, addi-
tional studies are warranted to further examine the postprandial lipid-lowering eect of
pramlintide(Fig.1.12)[16].
1.5.1 Long Time Therapy
As dened before a good therapy must be within an A1C variation of <7%. In a 12-
month study duration has been investigated the long-term glycemic control in patients
with insulin-requiring T1 and T2 diabetes[20]. In all cases pramlintide were administered
in addition to patients existing insulin regimens. These studies consistently demonstrated
that the addition of pramlintide to pre-existing insulin therapy improved overall glycemic
control in patients with either type 1 or type 2 diabetes, as evidenced by signicant reduc-
tions in A1C of about 0.5-1.0% from baseline and about 0.3-0.5% compared to placebo .
Furthermore, the proportion of patients who were able to achieve ADA glycemic targets
(A1C <7%) were two- to threefold greater with pramlintide plus insulin than with insulin
alone. Stratication by baseline body mass index (BMI) revealed that pramlintide tended
to prevent weight gain in patients who were lean at study entry and induced increasing
16Figure 1.12: The circles line is the excursions at baseline (i.e. at the beginning of treatment,
week 0), the squared line is in the middle of treatment (week 4) and the triangle one is the
end of treatment (week 6). We observe that pramlintide eect lowers the glucose excursion
(A), glucagon excursion (B) and triglycerides excursion (C), for a long term study.
17Figure 1.13: Reduction of Hyperglycemia status and increasing of euglycemic range, in
week 4, i.e. in the middle of pramlintide treatment.
18Figure 1.14: Sensor's point of view of a single subject. Similar results as shown in Fig 1.13.
19amounts of weight loss in overweight and obese patients. This weight loss averaged 1.6 kg
in patients with type 1 diabetes with a BMI >27 kg/m2 and 2.4 kg in patients with type 2
diabetes with a BMI >35 kg/m2 after treatment with pramlintide for 26 weeks. 56 pooled
analyses of data from the long-term trials in patients with type 1 or type 2 diabetes showed
that twice the number of pramlintide than placebo treated patients achieved a simultaneous
reduction in both A1C and body weight. The long-term improvement of glycemic control
with pramlintide was not associated with an increase in the overall event rate of severe
hypoglycemia, as it is often seen when glycemic control is improved by intensication of
insulin therapy [19](Fig 1.15).
1.5.2 BG Variability
A1c, like others measures of long-term average glycemia, is not designed to capture the rate
and the magnitude of acute BG 
uctuations, which aect the glucose variability. First, in
clinic trial, only 7-point glucose proles, taken at 3-month intervals, are usually available
for analysis of glucose variability. Second glucose variability is quantied using standard
deviation, which has been shown to be a poor measure of variability-associated risks. A
recent report conrmed that: variability in blood glucose (BG) around a patients mean
value has no in
uence on the development or progression of retinopathy or nephropathy.
However, the conclusions of this report were conned to microvascular complications. A1c
is so insucient for determining the risk for the full spectrum of complications associated
with diabetes. This is alarming because the hyperglycemic excursions, usually not detected
by A1c, are a factor that contributes to morbidity associated with diabetes9. Therefore
it's needed a therapy that lowers A1c but at same time minimizes acute BG extremes.
Pramlintide could be an answer. It could be calculated, using the SMBG10 readings, a
quadratic risk function: the left wing of the quadratic risk function is LBGI, an estimator
that calculates the risk of hypo., and the right wing is HBGI, which calculates the risk of
hyper. Put them two together the quadratic function is still created, with the minimum
value of 0 achieved at BG=6.25 mmol/L (112.5 mg/dL), which its a safe euglycemic reading.
The readings are plotted in a scatterplot in Fig 1.16.
The BG is calculated like the dierence between the y (the p.p. value) and x (the prepran-
dial value) of a patient. We see from Fig 1.16 that the black cluster is moved down respect
the placebo (white) one, which is a good thing, meaning that the pramlintide treated sub-
9Recently it has found a mood and cognitive disturbance when severe hyperglycemia occurs.
10Self Monitored Blood Glucose.
20Figure 1.15: Statistical signicance is denoted by P <0.05. In both types of diabetes, ad-
dition of pramlintide to existing insulin therapy led to signicant and sustained reductions
in both A1C (A) and body weight (B).
21Figure 1.16: (AC) Scatterplots of the pre- to postprandial glucose excursions observed
during the maintenance phase of the study at breakfast, lunch, and dinner, respectively.
The data of the pramlintide group (black squares) are generally below the data of the
placebo group (circles), indicating lower postprandial glucose excursions on pramlintide.
22jects reduced their variability (below an imaginary bisector). Only breakfast has a little
movement to left risking hypo. but its not relevant. The values are calculated and reported
in Fig 1.17.
Figure 1.17: Eects of pramlintide on the dynamics of pre-to postprandial BG excursions
and on the risks of hypoglycemia and hyperglycemia.
It is important to point out that the reduction of BG variability is independent from the
reduction of average glycemia. Indeed the glycemia average improvement (lowering) hap-
pens even in placebo group. Being A1c bounded to the BG average this is consistent to the
previous consideration. Moreover the insulin injection amount s reduced during treatment
of 30-50% and not raising the hypoglycemia risk [21].
23Chapter 2
Meal Simulation Model of
Glucose-Insulin system
2.1 Introduction to Global Model of Glucose/Insulin Sys-
tem
The important work, to which I will always refer, is the Meal Simulation Model of the
Glucose-Insulin System in normal humans by Cobelli, Dalla Man, and Rizza[22]. The
notable thing of this model is that the provided main glucose-insulin 
uxes, e.g. Ra, en-
dogenous glucose production, utilization of glucose and so on, are estimated in independent-
model way, to estimate the sub-models parameters[23]. The whole system is decomposed
into subsystems; each one has its estimated parameters with estimation methods (Fig.2.1).
For example the Glucose System and Insulin System are represented in Fig.2.2 . The model
is also good for simulating the daily life and takes care about the meal taken orally, which
makes this model more complicated but more realistic as well (useful for oral test etc.).
The identication process has been made using forcing function and using average datas
of a population of 204 normal subjects. Also an addition study on 14 types 2 diabetes has
been conducted.
24Figure 2.1: Scheme of the glucose-insulin system which puts in relation the measured
plasma concentration, i.e. glucose G, and insulin I, and glucose 
uxes: Ra, production
EPG, utilization U, renal extraction E; and to insulin 
uxes: secretion S and degradation
D.
25Figure 2.2: Scheme of glucose subsystem.
2.1.1 Glucose Subsystem
Here It is presented in detail only one subsystem. I present only one of the many sub-
system's equations, the glucose subsystem (Fig. 2.2). By extension the other systems are
described in the same way. The model identication is available in [32, 33]. The glucose
model is composed by two compartments described by equations:
8
> <
> :
_ Gp(t) = EGP(t) + Ra(t)   Uii(t)   E(t)   k1  Gp(t) + k2  Gt(t) Gp(0) = Gpb
_ Gt(t) =  Uid(t) + k1  Gp(t)   k2  Gt(t) Gt(0) = Gtb
G(t) =
Gp
VG G(0) = Gb;
(2.1)
where Gp and Gt are glucose masses in plasma: rapidly equilibrating tissue, and slowly
equilibrating tissue respectively (mg/dl). G (mg/dl) is the plasma glucose concentration.
Sux \b" denotes basal state; EPG is the endogenous glucose production (mg/kg/min); Ra
is the glucose rate of appearance in plasma (mg/kg/min); E is renal excretion (mg/kg/min);
Uii is the insulin-independent tissue's glucose utilization and Uid is the insulin-dependent's
glucose utilization (both mg/kg/dl). VG is the distribution volume of glucose (dl/kg); k1
26and k2 are the rate parameters (both min 1). At basal steady state endogenous production
EGPb equals glucose disappearance, i.e. the sum of glucose utilization and renal excretion
(which is normally zero in normal subjects):
EGP = Ub + Eb: (2.2)
Parameter values of VG, k1 and k2 are reported in Fig 1.20, in glucose subsystem kinetic
process. The 
uxes of interest are estimated using forcing functions strategy as shown in
Fig. 1.21, using nonlinear least squares.
The simulation of an entire day using the model is well presented in Fig. 1.22 for a normal
human. Overall this model is based on virtually model-independent measurements of the
various 
uxes occurring during the day. So for the diabetes type 2 population studied is
used the same model but a dierent parametric portrait. The model's limits, of course,
exist and they are: the not concerning about other hormones in
uences (e.g. the glucagon
action); the \glucocentric" nature of model (no fatty acids interactions); The parameters
are quite xed and sometimes they have daily changes, so their description should be im-
proved. And nally, this is a mean model and, of course, does not account so well for inter
subject variability.
27Figure 2.3: Model parameters of normal and type2 average diabetic subject.
28Figure 2.4: Endogenous Glucose Production (EGP) estimation strategy (top left panel);
glucose Ra (top right panel); glucose utilization (bottom left panel); insulin secretion (bot-
tom right panel). The input of each block is a forcing function, the outgoing arrows are
model outputs.
29Figure 2.5: Whole day simulation of a normal (continuous) and of other experiments
(modied some parameters). We see plotted the model prediction of plasma concentrations
and 
uxes with breakfast at 8.00 am (45g of glucose), lunch al 12 p.m. (70g), and dinner
at 8 p.m. (70g).
302.1.2 Introduction to Oral Model System
The Oral Model System is a model which is integrated as a subsystem of the previous model,
2.1. It is called Gastro-Intestinal Tract (See Fig.2.1 and Fig.2.4 upper right)[24]. An oral
ingestion model of glucose is very important because is used in many clinical test to assess
glucose tolerance on humans (OGTT) and obviously about experiments with everyday
meals. As we can see from Fig.2.4 upper right, the input is the meal ingested (amount of
glucose in mg) and the output is the glucose rate of appearance Ra (mg/kg/min).
Figure 2.6: Rates of appearance measured with the multiple
tracer tracer-to-tracee clamp technique during OGTT (left) and
meal (right); grey area represents range of variability.
There are two old mod-
els proposed (model A
and B of Fig.2.7, upper)
but after the availability
of gold standard data of
Ra (Fig. 2.6) provided
by [30, 31], the model C
and D (Fig. 2.7, lower)
are proposed. The phys-
iology process, used in
the models, is: the in-
gestion of glucose, then
glucose is absorbed in
the upper gastrointesti-
nal tract, then it's trans-
ported to the splanch-
nic bed (mostly the liver)
and, nally, reaches the peripheral circulation. Moreover many authors agree that the gas-
tric emptying of liquids occurs exponentially and depends on the size of the meal, its
energy and the amount of nutrient in stomach. But with increasing of nutrient caloric
content, there is a deceleration from the exponential model to a closer approximation of
linearity[34]. Thus, while liquid are non-linearly emptied, the solid part has a linear empty-
ing. Therefore we need two compartments for stomach[35]. For obviously reasons, related
to the non-linearity of gastric emptying, the model A (Lehman and Deutsh model), the
model B ( Elasho Model) and, as we could see, the Model 1, are too simple and not good
for achieve a good modeling result. It's considered as reference and most reliable model,
the fourth, i.e. that one called Model D, in Fig.2.7, lower panel on the right. For having
a more complete work it's considered the estimation for OGTT test, i.e the the input is
just glucose(75g), and Meal test, i.e the intake of a mixed meal (45% carbohydrates, 90g
of glucose) .
31Figure 2.7: The four proposed models.
32Gastro-Intestinal tract model
In Fig.2.7, model D, lower panel on right, as previously said, is the most reliable, and it is
considered as reference of this work. It is composed by three compartments: glucose transits
through the stomach, which is composed by two compartments, one for solid phase sto1
and one for liquid phase sto2, and it goes to small intestine. So the model is represented
by a chain of three compartments, with equations:
8
> > <
> > :
_ qsto1(t) =  k21  qsto1(t) + D(t)
_ qsto2(t) =  kempt  qsto2(t) + k21  qsto1(t)
_ qgut(t) =  kabs  qgut(t) + kempt(qsto(t))  qsto2(t)
Ra(t) =  f  kabs  qgut(t)
(2.3)
where qsto1 and qsto2 are the amounts of glucose in the stomach, solid and liquid respectively
and qsto1+qsto2=qsto. (t) is the impulse function, D is the amount of ingested glucose; qgut
is the glucose mass in the intestine; k21 is the rate of grinding, i.e. how the food passes
from solid to liquid phase; kempt is the rate of gastric emptying (it is linear in model C);
kabs is the rate of intestinal absorption; f is the fraction of the intestinal absorption which
actually appears in plasma ( in fact a part of glucose is \sequestered" by splanchnic organ
for their activity) and it is expressed as follows:
f =
R 1
0 Raogtt=meal(t)
D
(2.4)
where the numerator is the area under the curve (AUC) of Ra (Raogtt or Rameal). We
note from the gold datas that Raogtt has three phases in its graph and Rameal has two
(Fig. 1.23): OGTT shows a peak at 30 min, a plateau at 120 min and a rapid decrease
to zero in the last part; in the MEAL Ra we observe the peak at 60 min (re
ecting the
slower emptying of mixed meal components), and the the curve goes to zero without a
plateau. Clearly a linear model cannot capture these features. So the Model 2 has to be a
non-linear approach. It's described by the equations (1.3) and (1.4), in which it contains
only a non-linearity in the gastric-emptying denition, i.e. in the kempt parameter, which
is not a constraint but it's dependent on the total amount of glucose in the stomach qsto
as follows:
kempt(qsto) = kmin +
kmax   kmin
2
ftanh[(qsto  bD)] tanh[(qsto  cD)]+2g (2.5)
33with
qsto(t) = qsto1(t) + qsto2(t) (2.6)
where kempt is maximum (=kmax) when the stomach contains the amount of the ingested
glucose D, i.e. at the beginning of the experiment, then it decreases with rate  to a
minimum, kmin, then it recovers back again to its maximum kmax with a rate of , when
the stomach is empty (Fig.1.25). Then, b is the percentage of dose for which kempt decreases
at (kmax kmin)=2 and c is the percentage of dose for which kempt is back to (kmax kmin)=2.
They both correspond to 
exes points. All the measure units (Model 1 and 2) are of course
the same of (1.1). For the estimation of  and  it's imposed, considering that kempt=kmax
for both qsto = D and qsot = 0, the following equations:
 =
5
2  D  (1   b)
(2.7)
 =
5
2  D  :c
(2.8)
.
If c is very small kempt remains at level kmin till the stomach is completely empty and (1.5)
simplies as:
kempt(qsto) = kmin +
kmax   kmin
2
 ftanh[(qsto   b  D)] + 1g: (2.9)
The Model 2 ts very well Raogtt and Rameal proles in both average as well as in each
individual (Fig. 1.26).
The estimations are made by nonlinear least squares, Ra error is assumed independent
and Gaussian with zero mean and unknown standard deviation (posteriori-estimated) and
negative Ra values are not considerate. To favor identication of Model 2, especially for
the meal studies, the constraint k21 = kmax has imposed.
Having c very small means that the kempt's curve doesn't recover the initial rate, in other
words, the kempt = kmin when the stomach is empty. As result for a MEAL test when it's
used either (1.5) and (1.9) we have an average kempt as shown in Fig.1.27., right panel,
where for qsto=0 we have a kempt dierent from kmax.
Overall the maximum gastric emptying is similar in the two tests but kmin, kabs, b and c
are lower in MEAL than OGTT. This agrees with the knowledge that glucose absorption
is slower if I eat a meal than a OGTT due the presence of other components, mainly fats,
34Figure 2.8: Qualitative plot of kempt as function of the amount of glucose in the stomach
qsto: it's kempt=kmax for both qsto = D and qsto = 0, i.e when stomach is full or empty.
which signicantly slow down gastric digestion : kMEAL
min <kOGTT
min and intestinal absorption
is consequently kMEAL
abs <kOGTT
abs .
The interesting feature of Model 2 is that its parameters are potentially usable to quan-
titatively characterize the dierent Ra pattern observed in various conditions, e.g., young
vs elderly, men vs women, diabetic vs non diabetic, even pramlintide treated diabetic
type 1 subjects vs regular treated diabetic type 1 subjects.
35Figure 2.9: Left panel is OGTT test and right is MEAL test. Upper panel is Lehman and
Deutsch model (broken line) vs the Elasho model (solid line) vs data (black dots). Lower
panel is Model 1 (broken line) vs Model 2 (solid line) vs data (black dots).
36Figure 2.10: Average gastric emptying rate estimated during OGTT test (left panel and
similar to the ideal one in Fig.1.25) and during MEAL (right panel). For the estimation of
the kMEAL
empt is used for 50% of patients (1.5) equation and for the others 50% the (1.9) one.
37Chapter 3
Dataset
The aim of the thesis is is to nd a parametric estimation model of the average patient
treated with Pramlintide using the clinic protocol written below, in this chapter, obtaining
a model to include in a simulator to prove the Pramlintide eect in silico. In fact, my
new subsystem model will be integrated to the model described in section 1.6, for a char-
acterization of the T1 diabetes regularly treated with insulin with the Pramlintide addition.
Major ndings of gastric emptying studies are that the physiological defense mechanism to
delay gastric emptying in response to postprandial hyperglycemia is impaired in patients
with type 1 diabetes[36]. The IAPP( amylin) in healthy subjects delays the gastric emp-
tying, leading BG to a slower Ra avoiding high glucose peaks. The important study of
Woerle and others oers a good protocol for my experimentation[37].
3.1 The Experiment Protocol
The study, issued in 2008, is about an healthy population (7 men and 3 women, n=10,
394 years of age, BW 804kg) and a diabetics type 1 population (8 men and 7 women,
n=15, 372 years of age, BW 763kg). Both populations has normal physical examination
and no gastric problems or nephropathy. All type1 patients receive continuos subcutaneous
insulin infusion therapy for at least 3 months before the study with a good glycemic control
(A1C 7.3  0.2%) without severe hypoglycemic episodes. Three days before the test no
alcohol, no smoke or exercises with 200 g of carbohydrates daily. The healthy population
has been chosen not to have history of diabetes and to have a normal glucose response.
No food intake before 10 hours before the meal test. The breakfast time is from 7.00 am
to 7.30 a.m., and possibly within ve minutes. The T1 subject has the SMBG at 10 p.m.
38and 2 a.m. at the night before test due the adjustment of basal insulin to achieve the BG
concentration of 5 and 10 mmol/l respectively. The pramlintide amount for the designed
patients ( n=15) is 30g is injected subcutaneously in the lower abdominal wall and taken at
meal time. The postprandial Insulin infusion for euglycemic and hyperglycemic conditions
are: 6.40.9, 6.80.8, 3.50.8, 1.40.3 and 0.90.1islet equivalents/h at the times: 0-30,
35-60, 65-120, 240-330 minutes. The mixed meal is about 450 kcal (45% carbohydrates,
30% fats, 25% proteins) with glucose amount (D) of 50g (50000mg) containing tracers. For
the health subjects in hyperglycemia status other sugar is added in postprandial period
but for type 1 experiments is not.
3.1.1 Results
They induced hyperglycemia status in health and diabetes T1 subjects nding that the
feedback delay mechanism is completely absent in T1 subjects, as expected. In fact in
normal subjects when hyperglycemia was induced the amylin concentration went from 9 to
43 pmol/l postprandially so the gastric emptying was strongly delayed. For T1 diabetes the
same gastric emptying prole is detected for either euglycemic status and hyperglycemic
status due to the lack of amylin Fig(3.1).
Note that initial gastric emptying is greater in T1 patients. Hyperglycemia delays the
percentage of emptying rate only in healthy subjects (blue vs green plots), but there's no
dierence between the two diabetes emptying plots (euglycemic vs hyperglycemia, red vs
yellow plots). The pramlintide treated patients have a strong emptying delay, the gray line
plot, which is similar to the normal subject hyperglycemic pattern (green plot).
The others average 
uxes of all kind of populations are illustrated in Fig.3.2. where I note
that the subcutaneous pramlintide reduces the postprandial glucose in type 1 diabetic
patients (as expected). Moreover plasma insulin is not dierent between T1 with and
without pramlintide.
3.1.2 Rate of Appearance in type 1 diabetes treated with pramlin-
tide
A good observation is the rate of appearance, which is composed by two complementary
components: the endogenous, i.e. the internal glucose 
uxes appearing on blood, and ex-
ogenous, i.e. the external glucose 
ux appearing on blood. Amylin, so pramlintide, eects
both 
uxes ( liver derived function and meal derived function respectively, section 1.4).
The endogenous production is strictly correlated to glucagon action and recent studies
showed that IAPP and pramlintide suppress postprandial glucagon secretion[38, 39]. In-
deed, they found greater suppression of postprandial glucagon in type 1 diabetic patients
39Figure 3.1: A: gastric emptying in function of time after a meal test. Blue line is normal
subject in euglycemic condition; green line is normal subject in hyper.; yellow line is T1
diabetes in euglycemic; red line is T1 diabetes in hyper.; gray line is T1 in hyperglycemia
condition treated with pramlintide. B: Percent gastric retention, lag periods, 50% retention
time, percent retention at 60min. C: Inverse correlation of gastric retention at 45 min and
incremental plasma glucose concentration at 60 min. Comparison made using paired and
unpaired t tests within and between patients groups.
40Figure 3.2: Glucose concentrations on plasma at top panel; insulin plasma concentrations
at middle left panel; glucagon plasma concentration and amylin concentration at middle
right panel; Ra plots on the bottom panel. The blue circle line is the average healthy
subject; the green squared line is the average healthy subject in hyperglycemia; the yellow
line is average euglycemic T1 subject; red squared line is the average T1 subject in hyper.;
the gray line is the average T1 subject in hyper. treated with pramlintide. Comparison
made using paired and unpaired t tests within and between patients groups.
41when pramlintide was given (Fig.3.2, middle right panel), and a lower endogenous pro-
duction in pramlintide treated. But looking at the plots (Fig.3.2, bottom right panel) the
endogenous Ra is not aected by pramlintide usage! The reason why the endogenous pro-
duction is so similar using pramlintide or not is not so clear but the glucagon suppression
may have occurred or directly by an inhibitory eect of pramlintide on the pancreatic-cell
or indirectly via reduced eux of nutrients from the gut, because amino acids such as
arginine are known to stimulate glucagon secretion[40]. Thus, it remains unclear whether
the greater suppression of glucagon secretion is attributable to a direct inhibition of the
pancreatic-cells or to reduced in
ux of nutrients from the gut. However, because endoge-
nous glucose production is comparable in the placebo and pramlintide experiments in type
1 diabetic patients, the physicians believe that the pramlintide induces reduction of post-
prandial glucose concentrations and it is primarily due to the delay in gastric emptying.
So they skip the pramlintide's meal derived function considering only exogenous Ra as
eective Ra. On the other hand Ra (exogenous Ra) which was greater in diabetics than
healthy, with pramlintide action it is now reduced (bottom left panel 3.2, gray diamonds)
and the shorter peak is shifted to the right marking an important delay.
42Chapter 4
Oral Glucose Absorption Model
Identication
The reference model is the Model 2 illustrated at 1.6.2. The model is prior identiable. The
estimation method is the non-linear weighted squares with or without MAP1 estimator.
The all identication is implemented with MATLAB2 and/or SAAM II3. The two identi-
cations are for the average patient from clinical data test previously described (section 1.1,
Fig.4.1) in a rst place, then It's estimated the single patient's Ra.
1MAP: Maximum At Posterior: it's a Bayesian punctual estimator.
2MATLAB software by MathWorks Inc., R2012a.
3The Epsilon Group, University of Washington, 2011.
43Figure 4.1: The average Ra's pattern for T1 hyperglycemic patient (blue line); the average
Ra's pattern for T1 hyperglycemic patient treated with pramlintide.
4.0.3 Identication of the average type1 diabetic in hyperglycemia (only
insulin treated), PLACEBO
Recalling the Model's 2 equations (2.3) with the kempt as described in (2.5), the unknown
model's parameters are: kmax, kmin, kabs, b and c. The initial values, according with Fig.2.3
are: kmax = 0:06; kmin = 0:008; kabs = 0:08; b = 0:8; c = 0:4 (for the measurements units
see Fig.2.3).
The model's portrait is (Value, Estimation Precision) in following table:
with f = 0:83085 calculated as in formula (2.4). The prediction model is in Fig.4.2, upper
panel. The WRSS (Weighted Residual Sum Squared) is 20, whose weights residuals are in
Fig.4.2 lower panel.
44Figure 4.2: The model prediction (continuous line) vs data (red points), upper panel.
Weighted normal residuals, lower panel.
45Parameters Values CV [%]
kmax 0.0242 [min 1] 19
kmin 0.0095 [min 1] 6
kabs 0.094 [min 1] 58
b 0.79 [unit-less] 3
c 0.0817[unit-less] 13
Table 4.1: Average Diabetic subject, regularly treated with insulin, in hyperglycemia sta-
tus, i.e. placebo (PBO), identication.
As I can see from Fig.3.4 the t is good and the gastric emptying's plot is similar to the
healthy one, but obviously dierent in parameter's value. In fact the kabs is bigger than in
healthy subject: (kPBO
abs = 0:094min 1 > kHE
abs = 0:071min 1), showing that diabetes T1
in hyperglycemia has a faster glucose absorption. Then the c and b values are lower than
healthy ones: (bPBO = 0:69 < bHE = 0:79 cPBO = 0:008 < cHE = 0:17), which they give a
sort of slopes to the curve provoking dierent plot of the emptying. Even kmax is dierent
than healthy one but this gastric emptying respects the fact that the kempt is kmax either
with full and empty stomach.
4.0.4 Identication of the average type1 diabetic in hyperglycemia with
Pramlintide addiction
The average data for average T1DM in hyperglycemia and treated with Pramlintide is the
red plot in Fig.4.1. The initial values, according with Fig.2.3 is: kmax = 0:06; kmin = 0:008;
kabs = 0:08; b = 0:8; c = 0:4 (for the measurements units see Fig.2.3). The population
value are (prior information):
Parameter Bayesian Prior Value Bayesian Prior SD (CV %)
kmax 0.04 [min 1] 100%
kmin 0.004 [min 1] 10%
kabs { {
b { {
c { {
Table 4.2: Priors used in the Pramlintide average subject's Ra identication.
Recalling the model's equations (2.3) with the kempt as described in (2.5), the unknown
model's parameters are: kmax, kmin, kabs, b and c. The f is xed to the population value
[41], Fig.4.3, and the reasons are explained later in this section.
f = 0:9: (4.1)
46Figure 4.3: The f distribution for an healthy population. The mean is round 0.9 and it's
chosen as reference in simulation A.
The model's identication portrait is (Value, Estimation Precision):
Parameters Values CV [%]
kmax 0.043 [min 1] 50
kmin 0.0038 [min 1] 60
kabs 0.0056 [min 1] 11
b 0.99 [unit-less] 3
c 0.56[unit-less] 22
Table 4.3: Average Diabetic subject, regularly treated with insulin and Pramlintide, in
hyperglycemia status, i.e. PRAM, identication.
The prediction model is in Fig.4.4, upper panel. The WRSS (Weighted Residual Sum
Squared) are equal to 14 and they are at central panel, and the rate of emptying is lower
panel.
Assessment of the fraction of ingested glucose f with Pramlintide
The reason why the f is xed and not calculated with (2.4) from the available Ra datas
is because the observation window ( from -60min to +330min) is not sucient to see the
complete evolution of Ra. Indeed the integral of the formula should calculate the AUC
from the initial time zero (steady state) to a big value (virtually innite), in which the Ra
returns to zero (back to steady state). But as shows Fig.4.5 the nal part is missing. A
47Figure 4.4: A: Prediction model (continuos data) vs Prediction (red dots) of average Pram-
lintide patient. B: The weighted residuals of prediction model in A. Gastric emptying in
function of stomach glucose amount.
48solution could be an interpolation using the last sample ( Ra=1.022 mg/kg/min,t=330min)
and a virtual nal null samples when the digestion is supposed to be actual complete
(t=480min=8h), but It'll be dicult to choose what kind of interpolation is good, and
if a linear is chosen it's not clear how the slopes are (in Fig.4.5 it's chosen a random
interpolation, just for illustration purpose). So It's not a good way to proceed.
Figure 4.5: AUC assessment. The virtual pattern could go approximately to zero (end of
digestion) and its AUC (white AUC) gives the missing part of f which is not calculated
using the data, and according with theory should be about 0.2, to get the its actual nal
value of 0.9.
Calculating the f value using (2.4) from the Ra average data of T1DM Pramlintide treated,
in the dominium of my data ( the brown AUC on Fig.4.5):
fPRAM = 0:6898:
It should be expected that the f of a Pramlintide Ra is similar to a f of a healthy Ra
subject. Indeed the Pramlintide purpose is to bring the placebo Ra having a Ra similar to
the healthy one! Calculating the f from the average healthy subject:
fhealthy = 0:6959:
It's the value that it's expected, i.e. similar to fPRAM,( p<0.5). So the two f belong to
the same statistical population showed in Fig.4.3. That's why choosing f xed to the mean
49of population makes sense.
The identied model feel predicts Ra data and provides precise estimates of model param-
eters. The AIC and WRSS are the best related to the others simulation I've made and
residuals are a good representation of a white noise. The gastric emptying rate is dierent
from healthy one. Indeed at the beginning of the experiment, when the emptying rate of
stomach kempt(qsto) promptly decreases from kmax to kmin. This means that the kempt is
immediately slowed down resulting in a delayed gastric emptying. Observing the b value,
which close to one, it represents the fact that kempt is immediately slowed down to kmin.
Then the gastric emptying rate slowly increases and it recovers back to a constant value,
similar to kmax, till the stomach is empty. Its plot is consistent with a gastric emptying
delayed action of pramlintide respect to the gastric emptying in a type 1 diabetic regularly
treated with only insulin (Fig.2.4, lower panel).
4.1 Identication on single T1DM patient treated with Pram-
lintide
The T1DM Pramlintide average model, as presented previously, is well identied. But
what happened if I try to identify the model for a single patient? Is the model still good
for a individual patient, or is reliable only for the average patient? All this questions aim
to the same goal, i.e. the application of the average model to the single patient in order to
incorporate the eect of Pramlintide into the Meal Simulation Model of the Glucose-Insulin
system.
Before going into the single identication activity, many issues have to be underscored.
The single patients is aected by more noise than average patient, e.g measurement, envi-
ronment, physical noises. In this general situation the bayesian tools are fundamental. I
use the MAP estimator and I modify the prior information for a better t and estimation
precision at the same time. It must be noticed that the individual Ra are sometimes very
dierent among one other, pointing out how much the physiology is variable and compli-
cated. Moreover the data available for a patient is only the Ra measurement and not its
variance. So the identication of each patient will be made with unknown measurement
error, in which the SD will be estimated a posteriori. Other topic is the f constraint: it's
not possible to x the f to 0.9 as done before because it is a personal parameter, which in
this case cannot be xed to mean population value. Due the fact that f is priori unknown
I calculate it using (2.4) equation (for a 15 subjects' f distribution, see Fig.4.6).
50Figure 4.6: The f distribution; linear interpolation AUC added.
4.1.1 Identications of single patients: PLACEBO vs. PRAMLINTIDE
According with the identication theory the bayesian is avoided where not necessary.
51Placebo, PBO
The initial values are: kmax = 0:06min 1; kmin = 0:01min 1; kabs = 0:08min 1; b = 0:8;
c = 0:2 and used for subjects: 1,2,3,4,6,7,10,11,12,13,14,15; The initial value for subjects
5,8,9 and 13 are the same above but c=0.6. The Placebo (PBO) bayesian prior set is in
table 4.4 and 4.5.
Parameter Bayesian Prior Value Bayesian Prior SD (CV %)
kmax { {
kmin 0.001 [min 1] 10%
kabs 0.08 [min 1] 100%
b { {
c 0.2 10%
Table 4.4: Bayesian Priors used in the placebo (PBO) identications for subjects 3,7,12
and 15.
Parameter Bayesian Prior Value Bayesian Prior SD (CV %)
kmax { {
kmin { {
kabs 0.08 [min 1] 100%
b { {
c 0.7 100%
Table 4.5: Bayesian Priors used in the placebo (PBO) identications for subjects 5,8,13.
Pramlintide, PRAM
Parameter Bayesian Prior Value Bayesian Prior SD (CV %)
kmax { {
kmin 0.001 [min 1] 10%
kabs { {
b { {
c { {
Table 4.6: Bayesian Priors used in the Pramlintide (PRAM) identications. Used for
subject 1,3,4,8,9,12,15.
52Parameter Bayesian Prior Value Bayesian Prior SD (CV %)
kmax 0.06 [min 1] 100%
kmin 0.001 [min 1] 10% or 50%
kabs { {
b { {
c { {
Table 4.7: Bayesian Priors used in the Pramlintide (PRAM) identications. Used for
subject 2,5,6,7,10,13. Subjects 11 and 14 have the prior SD at 50% variation.
Predictive Models
As shown in Fig 4.15-16, where there are the identications portrait for all the 15 subjects,
the model can be identied with a good precision and as shown from the Fig.4.7 to 4.14,
the t is also good and satisfactory. In the PRAM identication, b is close to one value
in every subject. This means that the gastric emptying is very fast to decrease from its
maximum to its minimum, according to the Pramlintide's eects. In the g. 4.17-4.22
are reported the parameters distributions of 15 subjects. It is a small set of subjects for
extract some important information from the histograms. However from these distribution
it's very clear how the gastric emptying rate is modied after a Pramlintide addiction.
Looking into the parametric values of the two kind of patients it could be observed that
the parameters are quite dierent in values. This means a change of shape of the two kempt
plots. The Pramlintide's gastric emptying is the usual seen before for the average subject,
with a rapid decreasing from kmax to kmin and a slow increase back to the maximum value.
This means that b is decreased, close to one, and c is decreased. The p-values could be
calculated but it's clear that the dierences are not due casualty, but to a remarkable drug
eect.
53Figure 4.7: The 15 subjects Placebo's identication parameters.
54Figure 4.8: The 15 subjects Placebo's identication parameters.
55Figure 4.9: Upper: PBO vs PRAM identication of subject 1. Lower : PBO vs PRAM
identication of subject 2.
56Figure 4.10: Upper: PBO vs PRAM identication of subject 3. Lower : PBO vs PRAM
identication of subject 4.
57Figure 4.11: Upper: PBO vs PRAM identication of subject 5. Lower : PBO vs PRAM
identication of subject 6.
58Figure 4.12: Upper: PBO vs PRAM identication of subject 7. Lower : PBO vs PRAM
identication of subject 8.
59Figure 4.13: Upper: PBO vs PRAM identication of subject 9. Lower : PBO vs PRAM
identication of subject 10.
60Figure 4.14: Upper: PBO vs PRAM identication of subject 11. Lower : PBO vs PRAM
identication of subject 12.
61Figure 4.15: Upper: PBO vs PRAM identication of subject 13. Lower : PBO vs PRAM
identication of subject 14.
62Figure 4.16: PBO vs PRAM identication of subject 15.
63Figure 4.17: Upper: kmax distribution, PBO vs. PRAM. Lower: kmin distribution, PBO
vs. PRAM. Set of 15 T1DM subjects.
64Figure 4.18: Upper: kabs distribution, PBO vs. PRAM. Set of 15 T1DM subjects.
65Figure 4.19: Upper: b distribution, PBO vs. PRAM. Lower: c distribution, PBO vs.
PRAM. Set of 15 T1DM subjects.
66Chapter 5
In Silico Experiments
The aim of the following chapter is to try to include the Pramlintide eect into a Glucose-
Insulin simulator for diabetes type 1[42]. This simulations, are also called in silico because
it's a simulation of a biological system on a calculator, i.e. using numerical strategies.
5.1 Placebo vs. Pramlintide
The eect of Pramlintide is to try to lead the diabetic subject to have the closest BG
control as a normal subject. To see the dierence between the reference, placebo, and the
Pramlintide treated, we must observe the parametric dierence as shown in Fig.5.1. The
dierence between placebo and pramlintide (with 30g dose) is expressed by the following
formula:
pi =
pPRAM
i   pPBO
i
pPBO
i
 100 (5.1)
, where pi is the vector 5x1, containing the dierences in % between the parameter
vector of placebo and the parameter vector of Pramlintide action, with dose at 30g, for
the subject i. Applying (5.1) to each subject the Fig. 5.1 is obtained.
In Table 5.1 are reported in the bottom the mean dierences collected among 15 T1DM
subjects. it could be seen that the kmax of a Pramlintide is greater in average of 79% than
a kmax of placebo. The same is for b and c of Pramlintide, greater in average than placebo
respectively of 49% and 529% . On the contrary the kPRA
abs is lower than placebo of 93%.
It's well expected, that in Pramlintide either b and c grow.
67Figure 5.1: Dierences, in %, of the two parameters vectors, for each subject. Formula 5.1
is used. The minus means that PRAM is increased from PBO and vice versa.
685.2 In silico Open-Loop experiments
The next step is to evaluate Pramlintide eect on a simulation of 100 in silico subjects. In
other words including the Pramlintide action on the GIM: Glucose-Insulin Model, devel-
oped by Chiara Dalla Man, Davide Raimondo, Robert Rizza and Claudio Cobelli[42]. The
GIM version which is running is the one approved by FDA and developed by Dalla Man
et al.[43]. An important matter is that the simulation is in OPEN LOOP strategy control
because it's a simulation to underline the Pramlintide's eects more than controlling pur-
poses. A population of 100 T1DM is created by simulation GIM1. The simulations time
is a day (24h) and there is one meal: at 8.00 a.m. 50g of sugar. The insulin control is
always in OPEN-loop method for the whole day (Fig.5.2). Using as working condition the
Pramlintide's dose of 30g for all the 100 subjects the plot is represented in Fig.5.3. To
quantitatively determine the safety and ecacy of the Open loop therapy with and without
Pramlintide, I will use the CVGA (Control-Variability Grid Analysis) grid-plots. It is a
population index which shows how good is a treatment over a period of time (in this case
a day)[46]. Each dot on the grid represents a subject and can be on dierent areas of the
grid: A: Accurate Control (bright green); Lower B: Begin deviations into hypoglycemia;
B: begin control deviations; Upper B: begin deviations int hyperglycemia; Lower C: over-
correction of hyperglycemia; Upper C: over-correction of hypoglycemia; Lower D: failure
to Deal with hypoglycemia; Upper D: failure to Deal with hyperglycemia; E: Erroneous
control (red);
it is clear form Fig.5.4 upper, that a normal treatment, placebo, the cluster is on A and
B zone, i.e. the therapy is accurate with important deviations on hyperglycemia. Form
Fig.5.4, lower, it is clear that the the therapy, Pramlintide at 30g, maintains the main
cluster in A, but takes some subjects in Lower B and Lower C, showing a deviation to
hypoglycemia. Moreover is evident from the BG plots how the Pramlintide mean (bold
line of Fig.5.3, upper) is lower and smoother than the average placebo BG pattern (bold
line in Fig.5.2), according to the Pramlintide eects on BG control.
The empirical method to include Pramlintide's eect, it is to modify the subject's placebo
parameters (originally loaded), and multiply them for the dierences, that they have been
founded in Table 5.1. So for subject i, its new parameters' vector, which is loaded in the
simulator to include the Pramlintide's eects is equal to: pi
PRA= pi
PBOp=100, where
pi
PBO is the subject parameters vector of the rate of appearance (Rai), and p is the
vector represented in Table 5.1 containing the average parameter dierences.
1In order to simulate a type 1 subject, in the simulator GIM ,the insulin secretion module (present in
healthy or type 2) is substituted by a subcutaneous insulin infusion module and higher endogenous glucose
production is induced to create a typical basal glucose of a type 1 diabetic. All other parameters are kept
at values of the normal subject (subject assumed in a good control)[44].
69Figure 5.2: Blood Glucose patterns for 100 in silico T1DM subjects normally treated with
insulin,i.e. placebo. The bold line is the mean blood glucose path.
70Figure 5.3: Upper: Blood Glucose patterns for a 100 T1DM subjects treated with 30g
of Pramlintide. Lower: Rate of Appearance of 100 T1DM subjects treated with 30g of
Pramlintide. The bold lines are the mean patterns.
71Figure 5.4: Upper: cvga grid of Placebo treated set. Lower: cvga grid of 30g of Pramlin-
tide treated set. See the Pramlintide set's cluster shifting to the bottom right, indicating
a lowering of BG respect the placebo.
72Chapter 6
Dose-Response
The dose-response relationship describes the change in eect on an organism caused by
diering levels of exposures (doses of Pramlintide) to a stressor (T1DM) after a certain
exposure time. In other hand it'll be evaluated the eect of dierent amounts of Pram-
lintide to a T1DM in silico, using dierent doses from the usual reference of 30g. The
Figure 6.1: Dose-Response Graphs: in this experiments it's assumed the linear one.
73relationship between dose and response is a graph X-Y, where the response, Y, is the eect
of Pramlintide. If the Pramlintide dose X is increased, the Y increases, i.e. increases the
action of the drug. Usually a drug has a sigmoidal behavior or parabolic, in our case, due
the lack of data, a dose-response, starting with a linear model, will be taken (Fig.6.1).
6.1 Extraction of the response
Being the response linear, I obtain the relationship dose-response calculating two note
points of the graph: the rst one is for zero dose (placebo), the second one is at 30g dose
(the known case already studied) (Fig.6.2).
Figure 6.2: The two known work points: placebo at dose=0, and Pramlintide already
studied at dose=30g.
From Placebo (rst work point) to a Pramlintide normal treatment (second work point)
the Pramlintide lowers the Ra's peak of 33% (1.36 mg/kg/min=7.57mol/kg/min) and
induces a Ra delay of about one hour (according with the amylin eects). But these
are only qualitative results and I need more precise informations to evaluate the dierence
between the two points to estimate a proportional law for two generic points. So the eect of
Pramlintide is all included in the experiment identication parametric vector p, e.g. all the
information of dose=0 is included in the p0 values. From Fig.5.1 it's shown the parametric
dierences between the two known work points. It can be used the same dierence to
evaluate the eect between other two generic work points, knowing the proportionate
relationship (concept of linear dose-response model for Pramlintide in this case).
746.1.1 Simulation in silico with several doses of Pramlintide
The following experiments use dierent Pramlintide dosages with the previous hypothesis
of linear relationship in dose-response. All the simulations are implemented in GIM, with
a morning breakfast (8.00 am) of 50g of glucose. The simulation will be for: 10 ,20 ,30 ,40,
60 and 90g dose represented from Fig.6.3 to 6.8. Another information is given by Fig.6.9,
i.e. the CVGA grids for each dosage.
From the plots It's clear that from 0 to 30 g dosage, the Pramlintide intensity increases
with the Pramlintide's eects, as expected. But from the dose of 30g onwards, more
increasing hasn't any eects on the body, in fact for dose 40,60 and 90 g the plots are
basically the same, with not remarkable dierences, the cvga show that the cluster shifts
from A zone to C, indicating a lowering of BG in the therapy. This is because 30g dosage
is probably the most eective dose and afterward, no eects are evident, in other words
30g is a threshold for the Pramlintide eects on human body. This makes me think that
the actual dose-response shape is parabolic with 30 as a upper threshold (Fig.6.10).
75Figure 6.3: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=10g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=10g).
The bold path is the mean of the Ra paths.
76Figure 6.4: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=20g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=20g).
The bold path is the mean of the Ra paths.
77Figure 6.5: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=30g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=30g).
The bold path is the mean of the Ra paths.
78Figure 6.6: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=40g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=40g).
The bold path is the mean of the Ra paths.
79Figure 6.7: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=60g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=60g).
The bold path is the mean of the Ra paths.
80Figure 6.8: Upper: Blood Glucose patterns for 100 in silico T1DM subjects with Pramlin-
tide addition (dose=90g). The bold path is the mean of the BG paths. Lower: Rate of ap-
pearance patterns for 100 in silico T1DM subjects with Pramlintide addition (dose=90g).
The bold path is the mean of the Ra paths.
81Figure 6.9: CVGA grids for treatments at various dosages of PRamlintide for 100 T1DM
subjects set. A: cvga grid, using 10g dose. B: cvga grid, using 20g dose. C: cvga grid,
using 30g dose. D: cvga grid, using 40g dose. E: cvga grid, using 60g dose. F: cvga
grid: using 90g dose. 826.1.2 Carbo Ratio assessment
The most eective result there is for 30g in which the Pramlintide planes the post-prandial
excursion, i.e. no evident BG variability is seen after the meal (Fig.6.5). It is evident that
some subjects go in hypoglycemia area after meal. Despite the fact it's not the aim of
this thesis the system control, something could be said about. The CR (Carbo Ratio), i.e.
the grams of carbohydrate that are approximately covered by 1 unit of insulin, is subject
dependent. In this kind of simulation the CR represents the only point that could be tuned
to reduce the insulin given, according to the clinical trials, where the insulin given is about
30% less. An in silico try has been done when the CR is increased for everyone of 25%,
and the results are in (Fig.6.10), in which less hypoglycemic episodes are observed.
83Figure 6.10: Experiments in silico with 100 T1DM subject treated with 30g of Pramlin-
tide. Here there is also the addition of an increase of CR of 25% to get a better BG control.
Upper: Blood Glucose patterns, with mean bolded. Lower: CVGA plot.
84Chapter 7
Conclusions and Prospectives
Even though in Europe this new drug is not commercialized, USA seems to be more
optimistic about it. In fact it's clear from the tests developed in this thesis that Pramlintide
addition to a normal treatment (placebo) lowers the blood glucose after a meal. Not only
helps to deal with hyperglycemia health issues, but reduces the blood glucose variability,
which could lead to more dangerous problems. Pramlintide acts like the hormone amylin,
which is absent in T1DM, slowing the gastric emptying. The gastric contribute to blood
glucose control, seems to be more important day after day, where not only the amylin is
involved, but also other hormones, as GLP etc.. Slowing the gastric emptying, it's not
the only action of Pramlintide. It Reduces the secretion of glucagon, leading the system
to have less endogenous glucose. Despite the fact the main action of Pramlintide is to
slow the gastric emptying, the second eect should not be neglected, and could be a future
aim.
The identication of the action model of the pharmacodynamics of this drug has been made
with a good model, the best in literature, which considers the nonlinearity of the problem.
A point should be made: the b value tends to one, not only for the average, but for all
the subject's identications. This is true, because it means that a great slowing in gastric
emptying happens and it is visible from the kempt plot, in which it starts from its maximum
value kmax and decrease quickly to kmin as shown in Fig.7.1. Physiologically talking this is
fact is not possible. So a question arises, is this model reliable? Yes it is, even if it has this
lack of coherence with physiology (b goes to one and c is small). In fact the identication
for the 15 subjects made, is reliable and with a good precision. About the identication a
note should be pointed out: the standard deviation of the error is not known. In the glucose
models identication the CV is usually put constraint at 2%, here in Rate of Appearance
it's not possible to do that.The Ra derives from a complex extraction using a triple-tracer
approach to assess the postprandial glucose metabolism 
uxes, as Ra[47]. Also to aect
85Figure 7.1: Gastric Emptying for the average subject treated with Pramlintide (30g); the
red circle points the physiological incoherence of the model.
the identication occur all the errors deriving from the complex measures [47]. After all
good results are obtained. Moreover, a hint could be, to evaluate the inter variability of the
15 subjects calculating the covariance matrix, which it wouldn't be diagonal and extract a
stochastic function for insertion in the silico experiments.
After the identication of the action model, an inclusion in silico has been done. Here is
important to underscore the open-loop control. In this control is more easy to assess the
Pramlintide eect, which is the actual purpose of this thesis. Besides using high dosage
of drug it takes the system to have some subjects in hypoglycemia. To try to correct
them a rst step should be that one to correct for each subject the CR or to use a closed
loop control. It has been done for simplicity an automatic increase of CR for everyone
of +25%, and the number of subjects that are in hypoglycemia, are decreased (only in
open-loop).
Using the Pramlintide at 30g dose, as expected from clinical trials, is the best choice. In
fact trying all the doses, 30g seems to be the most eective therapy among them, in terms
of Pramlintide eects on human body of a type 1 diabetic. From 30g onwards no more
eect is given by Pramlintide. In general Drugs have a usual sigmoidal dose-response model
(Pramlintide seems to not be an exception) in fact after the threshold value of amount of
medicine, the body has all the drug's receptors full, and more amount given, would mean
that the overdose is in stand-by to enter into the target receptors and so it is inactive.
Pramlintide follows this phenomenon and in its case the threshold is 30g, as expected
(Fig.7.2).
Furthermore the usage of other dosages of Pramlintide doesn't bring the system in a bad
control, as shown in CVGA grids: none of the CVGA grids show a failure in control,
showing the fact that ,Pramlintide injected in a good-controlled system doesn't alter the
86Figure 7.2: Dose-Response Graphs: in this experiments it's assumed the linear, but a
threshold is evident for 30g of Pramlintide.
system. Speaking about systems point of view, Pramlintide action of lowering the output
(Ra) and BG variability, it could be seen as a low-pass lter, considering Pramlintide as an
agent which get rid of all the high speed components, i.e. the high frequency components.
So the controllers should prefer a conguration with Pramlintide to study and assess a
more easy BG control.
7.0.3 Future
In 2005, the Food and Drug Administration (FDA) has approved Symlin (pramlintide
acetate), an injectable medicine to control blood sugar for adults with type 1 and type 2
diabetes. Symlin is to be used in addition to insulin therapy in patients who cannot achieve
adequate control of their blood sugars on intensive insulin therapy alone. Symlin will be
the only therapy for the treatment of type 1 diabetes other than insulin. Patients with
type 2 diabetes already have several other types of oral therapies available. The safety and
ecacy of Symlin were studied in approximately 5000 patients. Overall Symlin therapy
was associated, in patients with both types of diabetes, with improvements in the control
of blood glucose and with weight loss. So-called "tight" control of blood sugar is desirable
87in all patients with diabetes in order to reduce risks for long-term adverse consequences
of the disease, including blindness, kidney disease, and vascular disease. Symlin is to
be used only in combination with insulin to help lower blood sugar during the 3 hours
after meals. Symlin will have a Medication Guide (FDA-approved patient labeling) and
a Risk Minimization Action Plan (RiskMAP) due to three areas of concern. First, the
principle risk associated with Symlin therapy is hypoglycemia, and this risk is greatest
in patients with type 1 diabetes and in patients with gastroparesis (motility problems of
the stomach-a long-term complication of diabetes). Second, the potential for medication
errors, specically mixing of Symlin with insulin in the same syringe, which can alter
the activity of the insulin, is addressed in the Medication Guide and in physician labeling.
Finally, the potential for o-label use in patients where the benet/risk prole has not been
characterized or demonstrated is also a concern and will be monitored by the sponsor. The
Medication Guide informs patients that Symlin should only be used if they are already
using their insulin as prescribed, but still need better blood sugar control; will follow their
doctor's instructions exactly; will follow-up with their doctor often; will test their blood
sugar levels before and after every meal, and at bedtime; and understand how to adjust
Symlin and insulin doses.
A whiteness to the fact that Pramlintide is a good drug, with a good potential, is the
recent (July, 2012) investment of Bristol-Myers Squibb, which agreed to buy Amylin Phar-
maceuticals, the maker of promising Pramlintide, in a complicated deal that is valued at
about 7 billion dollars. To help nance the transaction, Bristol-Myers teamed up with
AstraZeneca, which payed about 3.4 billion dollars in cash and will share in the prots
from Amylin's sales. To be more specic the deal is not only for Pramlintide copyrights,
in fact other couple of drugs and some projects are developed by Amylin Pharmaceuticals
(Pramlintide is the main bargain after all).
Pramlintide/Metreleptin
Another kind of treatment with Pramlintide may be with others drugs like Metreleptin, i.e.
the synthetic analog of human Leptin. Indeed the neurohormonal control of body weight
involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-
term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin
combination treatment led to marked, synergistic, fat-specic weight loss. To evaluate the
weight-lowering eect of combined amylin/leptin agonism (with pramlintide/metreleptin)
in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-
concept study was conducted in obese or overweight subjects. Combination treatment with
pramlintide/metreleptin led to signicantly greater weight loss from enrollment to week
20. The greater reduction in body weight was signicant as early as week 4, and weight
loss continued throughout the study, without evidence of a plateau. The most common
adverse events with pramlintide/metreleptin were injection site events and nausea, which
88were mostly mild to moderate and decreased over time. These results support further
development of pramlintide/metreleptin as a novel, integrated neurohormonal approach to
obesity pharmacotherapy[44].
T2DM Pramlintide Treated
The Pramlintide is having a good success in the treatment of type 2 diabetics treatments.
Most of the normal treatments are a combination of: Insulin, Insulin Secretagougues and
Insulin Sensitizer. All these treatments are often followed by weight gain, it's note the fact
that more insulin is given more you gain weight (but it's not clear which is the cause and
which the eect). The body mass increased is obvious not good for a type2. Moreover the
amylin activity is decient. From an important clinical trial, in which the Pramlintide is
given to type2, in addition to their normal treatment some interesting results are expressed:
less insulin is given and A1c nal achievement. The less insulin given equals less weight
gain, which is good, but the A1c is not correlated with the Pramlintide dose because we
will get the similar A1c without it. But the important thing is: more weight loss is evident
in patient with big BMI, e.g. obesity class III. Furthermore the combination of Insulin,
Pramlintide and Metformin (drug which reduces BG level acting on intestinal absorption
and liver production) brings the body to a more weight loss[45].
Future
The possible future developments is to include the Pramlintide in the articial pancreas
devices. The issues linked with this is to calibrate the controls, the engine and a strat-
egy to use another way of injection, which takes a synchronization with insulin control.
The articial pancreas is getting more sophisticated and more user-friendly, for instance
a project is being developed by University of Virginia, in which a Android application is
made to control your pancreas 
uxes directly from your smartphone: a street lighter image
on the screen tells you if you are in hypo. (red light) if you are in a sucient range (yellow
light) or in a good range ( green light). An addition of Pramlintide complicates the whole
system but the green light would be more frequent of course. Also we need to analyze
if there is some correlation between Pramlintide action and insulin sensitivity, if there is,
lots of controls might change. How to not cite a new and charming prospective of type 1
treatment studied by Southwestern Medical Center of Texas University. They say that if
we block the glucagon action the lack of insulin which causes the diabetes is not more a
disease! They have genetically modied some mice getting rid of their glucagon's receptors.
The mice respond the same way if the mice are with or without insulin, i.e. they don't
develop diabetes. They in fact arm that insulin is important for the grown of the body
but in adult age the insulin function is only to control the glucagon action! This open to
89a set of study of blocking the glucagon action.
Pramlintide in Europe
Amylin Pharmaceuticals, via a subsidiary called Amylin Europe Ltd., submitted Market-
ing Authorization Applications for SYMLIN(TM) (Pramlintide acetate) to the European
Agency for the Evaluation of Medicinal Products (EMEA) under the centralized European
procedure for the authorization of medicinal products in May 2001, but so far we don't
know anything about it. Besides in USA, San Diego exactly, in October 2007 Amylin
Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has
approved the SymlinPen 120 and the SymlinPen 60 pen-injector devices for administering
Symlin (Pramlintide acetate) injection. These new pre-lled pen-injector devices feature
simple, xed dosing to improve mealtime glucose control. `SymlinPen 120 and SymlinPen
60 oer patients improved convenience and accuracy,', said Daniel M. Bradbury, President
and CEO, Amylin Pharmaceuticals. `For people with diabetes using mealtime insulin, the
addition of Symlin can enhance glucose control with the potential for weight loss.'. Symlin-
Pen 60 features xed dosing to deliver 15, 30, 45, or 60 micrograms per dose. SymlinPen
120 features xed dosing to deliver 60 or 120 micrograms per dose. Both pen-injector
devices can be conveniently stored at room temperature not to exceed 86 degrees F (30
degrees C) after rst use. The pens are available to patients from December 2007.
Some Pramlintide engineer projects are nowadays developing in Italy, between the collabo-
ration of University of Pavia and Unifersity of Padova, in which I'm working on and belong
to.
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